Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00669071 · ClinicalTrials.gov registry record · Phase 4
Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma
A Phase 4 study, sponsored by Galderma R&D.
- Terminated
- Registry status
- Phase 4
- Development phase
- 56
- Enrollment target
NCT00669071 is a Phase 4 study that was terminated before completion, run by Galderma R&D. The registered enrollment target is 56 participants.
The verdict
NCT00669071, a Phase 4 study, was terminated before completion, sponsored by Galderma R&D.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 56 participants
- Enrollment target
Study Summary
This study is to evaluate the efficacy and safety of Tri-Luma® Cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) when used sequentially with a series of intense pulsed light (IPL) treatments in Subjects diagnosed with moderate to severe melasma during a 10 week treatment period.
Interventions
- DRUG Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%
- DRUG Cetaphil® Moisturizing Cream as Inactive Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00669071
The ClinicalTrials.gov registry entry for NCT00669071 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05% is the first listed.
NCT00669071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00669071 about?
NCT00669071 is a clinical study titled "Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma". This study is to evaluate the efficacy and safety of Tri-Luma® Cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) when used sequentially with a series of intense pulsed light (IPL) treatments in Subjects diagnosed with moderate to severe melasma during a 10 week treatment period.
What is the current status of trial NCT00669071?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 56 participants. The study started on 2008-01. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00669071?
The interventions under investigation include: Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05% (DRUG), Cetaphil® Moisturizing Cream as Inactive Control (DRUG).
Who is sponsoring clinical trial NCT00669071?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.